Valbiotis SA
PAR:ALVAL
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| FR |
|
Valbiotis SA
PAR:ALVAL
|
23.8m EUR |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.6B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.2B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR |
Loading...
|
Market Distribution
| Min | -1 220.2% |
| 30th Percentile | 34% |
| Median | 53.6% |
| 70th Percentile | 70.2% |
| Max | 509.6% |
Other Profitability Ratios
Valbiotis SA
Glance View
Valbiotis SA develops products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Valbiotis SA is -128.8%, which is above its 3-year median of -483.9%.
Over the last 3 years, Valbiotis SA’s Gross Margin has decreased from 28.5% to -128.8%. During this period, it reached a low of -1 796.6% on Dec 31, 2024 and a high of 88.8% on Jun 30, 2023.
